Updated Promising Zone Design Improves Workflow and Clinical Trial Design for Biotechs

Promising Zone Design was first introduced a decade ago as a method to estimate sample size. The method is still employed by biotech and pharma, with two recent updates offering additional power. The Constrained Promising Zone and the Predictive Power Promising Zone were introduced earlier this year.

“The design was initially meant to channel greater resources towards promising but underpowered studies, to ensure that they did not fail due to absence of adequate sample size. Since then, research into the Promising Zone Design has led to further questions about how to optimize such designs, and particularly how biotechs and pharmaceuticals might employ different strategies to achieve such optimization.” Read more here.

(Source: Esha Senchaudhuri, Cytel, 11/15/21)